- Home
- CSR vs PHAR Comparison
CSR vs PHAR Comparison
Compare CSR & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- PHAR
- Stock Information
- Founded
- CSR 1970
- PHAR 1988
- Country
- CSR United States
- PHAR Netherlands
- Employees
- CSR N/A
- PHAR N/A
- Industry
- CSR Real Estate Investment Trusts
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CSR Real Estate
- PHAR Health Care
- Exchange
- CSR Nasdaq
- PHAR Nasdaq
- Market Cap
- CSR 965.4M
- PHAR 951.7M
- IPO Year
- CSR N/A
- PHAR N/A
- Fundamental
- Price
- CSR $58.68
- PHAR $14.55
- Analyst Decision
- CSR Buy
- PHAR Strong Buy
- Analyst Count
- CSR 7
- PHAR 3
- Target Price
- CSR $68.57
- PHAR $30.00
- AVG Volume (30 Days)
- CSR 116.0K
- PHAR 14.4K
- Earning Date
- CSR 10-27-2025
- PHAR 10-23-2025
- Dividend Yield
- CSR 5.22%
- PHAR N/A
- EPS Growth
- CSR N/A
- PHAR N/A
- EPS
- CSR N/A
- PHAR N/A
- Revenue
- CSR $267,076,000.00
- PHAR $339,836,000.00
- Revenue This Year
- CSR $5.34
- PHAR $17.44
- Revenue Next Year
- CSR $2.80
- PHAR $8.46
- P/E Ratio
- CSR N/A
- PHAR N/A
- Revenue Growth
- CSR 3.44
- PHAR 22.44
- 52 Week Low
- CSR $52.76
- PHAR $7.31
- 52 Week High
- CSR $75.92
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- CSR 51.01
- PHAR 51.90
- Support Level
- CSR $57.62
- PHAR $13.18
- Resistance Level
- CSR $59.81
- PHAR $16.29
- Average True Range (ATR)
- CSR 1.35
- PHAR 0.55
- MACD
- CSR -0.05
- PHAR -0.04
- Stochastic Oscillator
- CSR 52.79
- PHAR 44.05
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.